Transgenomic, Inc. (NASDAQ: TBIO) is a global biotechnology
company advancing personalized medicine in cardiology, oncology and inherited
diseases through progressive diagnostic technologies, such as its revolutionary
ICE-COLD PCR™ (MX-ICP). Through this technology, the company provides more
sensitive and accurate mutation detection without major costs or impact to
current processes.
In May, Transgenomic built on the versatility of its MX-ICP
platform through the launch of a novel epidermal growth factor receptor (EGFR)
CLIA test for mutation detection in cancer patients, effectively opening the
door for more informed diagnoses, better treatment decisions and ongoing
patient monitoring moving forward. The first tests using this platform were for
the detection of EGFR T790M mutations, which have been linked to patient
resistance of current non-small cell lung cancer (NSCLC) treatment options.
“Launching our multiplexed ICE COLD-PCR-based CLIA mutation
detection service for oncologists and their patients is a major milestone for
Transgenomic and, we believe, an important advance for the field of precision
medicine,” Paul Kinnon, president and chief executive officer of Transgenomic,
stated in a news release. “The unsurpassed accuracy of MX-ICP and its ability to
produce highly sensitive and accurate results from small amounts of almost any
type of patient sample, especially liquid biopsies, allows broad use.”
MX-ICP has been shown effective in the detection of mutation
with a range of biofluid samples – including blood, plasma, serum, urine,
sputum and bronchial lavage – allowing for highly accurate, non-invasive
diagnostics of all known and unknown mutations.
In recent months, Transgenomic has leveraged the
considerable market for its diagnostic technologies and clinical and research
services to record improved financial results. During the first quarter of
2015, the company’s net sales were recorded at a 4 percent year-over-year
increase, with laboratory services sales increasing by over 30 percent for the
same period.
“The company made good progress in the first quarter in
strengthening our historical businesses while preparing for the imminent launch
of our breakthrough technology: Multiplexed ICE-COLD PCR™,” continued Kinnon.
“We achieved a double digit percentage increase in overall net sales excluding
the divested Surveyor product line, including a robust 32 percent increase in
the critical laboratory services segment.”
Moving forward, look for Transgenomic to continue building
on its recent progress in order to maximize industry growth. For prospective
investors, continued industry adoption of the company’s MX-ICP technology could
provide ample opportunity to realize sustainable returns in the years to come.
For more information, visit www.transgenomic.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment